OLYMPIA: TearCare treatment improves dry eye signs, symptoms
Sight Sciences’ TearCare treatment improved signs and symptoms of dry eye disease statistically significantly and clinically meaningfully, according to a study.
The OLYMPIA study compared a single TearCare treatment to a single LipiFlow (Johnson & Johnson Vision) treatment in a randomized, multicenter, masked study of 235 adults. Seventy percent of participants were women.
Tear breakup time (TBUT) and meibomian gland secretion score were statistically significantly improved at follow-up time points of 2 weeks and 1 month in both groups (P < .0001), thus meeting the study’s primary endpoint of noninferiority. Ocular Surface Disease Index (OSDI) was also statistically significantly improved, Jennifer M. Loh, MD, said in a poster presentation at the virtual Women in Ophthalmology Summer Symposium.
“Our study showed that a single TearCare treatment statistically and significantly improved the signs and symptoms of dry eye disease in 2 weeks,” Loh said.
Symptomatic relief, demonstrated by at least one OSDI category improvement, was achieved in a greater proportion of patients in the TearCare group than in the LipiFlow group, 72% vs. 59%.
“Even more interesting, a greater proportion of female patients [in the TearCare group] experienced clinically meaningful symptomatic relief in their dry eye symptoms,” Loh said.
Seventy-six percent of female subjects improved by at least one OSDI severity category at 1 month in the TearCare group compared with 56% in the LipiFlow group, according to the poster.
Collapse
Loh JM, et al. A novel, targeted, blink assisted, thermal eyelid therapy and meibomian gland clearance in the treatment of meibomian gland dysfunction (MGD): A prospective randomized controlled trial (OLYMPIA). Presented at: Women in Ophthalmology Summer Symposium; Aug. 21-23, 2020 (virtual meeting).
Read more about